Literature DB >> 24589722

Metabolic abnormalities in autosomal dominant polycystic kidney disease.

Zhiguo Mao1, Guoqiang Xie1, Albert C M Ong2.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and is known to affect all ethnic groups with a prevalence of 1:400-1:1000 live births. The kidney in ADKPD is characterized by the formation of numerous cysts which progressively expand and eventually destroy normal kidney structure and function. Cysts occur in other organs outside the kidney, most commonly in the liver, pancreas and spleen. Important non-cystic features include intracranial aneurysms and cardiac valve defects. Less well recognized are a range of metabolic abnormalities, which could be involved in cystic disease progression or be associated with other disease complications. In this review, we summarize the literature suggesting that metabolic abnormalities could be important under-recognised and under-treated features in ADPKD.
© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  ADPKD; NODAT; calculi; lipids; uric acid

Mesh:

Year:  2014        PMID: 24589722     DOI: 10.1093/ndt/gfu044

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

Review 1.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

2.  The consequences of increased 4E-BP1 in polycystic kidney disease.

Authors:  Sara J Holditch; Carolyn N Brown; Daniel J Atwood; Deepak Pokhrel; Sara E Brown; Andrew M Lombardi; Khoa N Nguyen; Ryan C Hill; Miguel Lanaspa; Katharina Hopp; Mary C M Weiser-Evans; Charles L Edelstein
Journal:  Hum Mol Genet       Date:  2019-12-15       Impact factor: 6.150

3.  Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease.

Authors:  Ladan Zand; Vicente E Torres; Timothy S Larson; Bernard F King; Sanjeev Sethi; Eric J Bergstralh; Andrea Angioi; Fernando C Fervenza
Journal:  Nephrol Dial Transplant       Date:  2015-11-27       Impact factor: 5.992

Review 4.  Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Evidence and Therapeutic Potential.

Authors:  Kristen L Nowak; Katharina Hopp
Journal:  Clin J Am Soc Nephrol       Date:  2020-02-21       Impact factor: 8.237

5.  Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).

Authors:  Kiyotaka Uchiyama; Toshio Mochizuki; Yosuke Shimada; Saori Nishio; Hiroshi Kataoka; Michihiro Mitobe; Ken Tsuchiya; Kazushige Hanaoka; Yoshifumi Ubara; Tatsuya Suwabe; Akinari Sekine; Kikuo Nutahara; Kazuhiko Tsuruya; Eiji Ishimura; Shinya Nakatani; Tadashi Sofue; Satoshi Tanaka; Ichiei Narita; Shoichi Maruyama; Shigeo Horie; Satoru Muto
Journal:  Clin Exp Nephrol       Date:  2021-04-29       Impact factor: 2.801

Review 6.  Autosomal dominant polycystic kidney disease: recent advances in clinical management.

Authors:  Zhiguo Mao; Jiehan Chong; Albert C M Ong
Journal:  F1000Res       Date:  2016-08-18

7.  Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease.

Authors:  Shosha E I Dekker; Aswin Verhoeven; Darius Soonawala; Dorien J M Peters; Johan W de Fijter; Oleg A Mayboroda
Journal:  PLoS One       Date:  2020-05-22       Impact factor: 3.240

8.  Serum Uric Acid and Progression of Autosomal Dominant Polycystic Kidney Disease: Results from the HALT PKD Trials.

Authors:  Godela M Brosnahan; Zhiying You; Wei Wang; Berenice Y Gitomer; Michel Chonchol
Journal:  Curr Hypertens Rev       Date:  2021

9.  New onset diabetes after kidney transplantation in patients with autosomal dominant polycystic kidney disease: systematic review protocol.

Authors:  Bo Yang; Sixiu Chen; Guang Yang; Changlin Mei; Albert Ong; Zhiguo Mao
Journal:  BMJ Open       Date:  2015-11-05       Impact factor: 2.692

10.  Autosomal Dominant Polycystic Kidney Disease Is a Risk Factor for Posttransplantation Diabetes Mellitus: An Updated Systematic Review and Meta-analysis.

Authors:  Alice Culliford; Nuvreen Phagura; Adnan Sharif
Journal:  Transplant Direct       Date:  2020-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.